Equisetin is an anti-obesity candidate through targeting 11 beta-HSD1

Obesity is increasingly prevalent globally, searching for therapeutic agents acting on adipose tissue is of great importance. Equisetin (EQST), a meroterpenoid isolated from a marine sponge-derived fungus, has been reported to display antibacterial and antiviral activities. Here, we revealed that EQST displayed anti-obesity effects acting on adipose tissue through inhibiting adipogenesis in vitro and attenuating HFD-induced obesity in mice, doing so without affecting food intake, blood pressure or heart rate. We demonstrated that EQST inhibited the enzyme activity of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), a therapeutic target of obesity in adipose tissue. Anti-obesity properties of EQST were all offset by applying excessive 11 beta-HSD1's substrates and 11 beta-HSD1 inhibition through knockdown in vitro or 11 beta-HSD1 knockout in vivo. In the 11 beta-HSD1 bypass model constructed by adding excess 11 beta-HSD1 products, EQST's anti-obesity effects disappeared. Furthermore, EQST directly bond to 11 beta-HSD1 protein and presented remarkable better intensity on 11 beta-HSD1 inhibition and better efficacy on anti-obesity than known 11 beta-HSD1 inhibitor. Therefore, EQST can be developed into anti-obesity candidate compound, and this study may provide more clues for developing higher effective 11 beta-HSD1 inhibitors. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.